Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

Fig. 2

Swimmer plot for the breast cancer (BC) patients included in the study Visualization of clinical follow‐up timelines for all study participants. The upper section represents patients who experienced clinical relapse (n = 6), while the lower section shows those without relapse (n = 14). Orange bars indicate the duration of hormone therapy (HT). Blood sampling events (n = 55) are represented by diamonds, with filled diamonds indicating minimal residual disease (MRD) positivity based on ctDNA detection

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us